Price
No data yet.
Social Signal Score
73
5d
74
1 mentions
—
30d
73
1 mentions
—
60d
73
1 mentions
—
90d
73
1 mentions
—
news: 1
Company Profile
- CEO
- Kevin R. Lind
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 65
- Beta
- 0.00
- Country
- US
Quote
Day Range
$26.01 – $29.56
52-Week Range
$16.12 – $35.29
Volume
$344.1K
Market Cap
$1.08B
50-Day Avg
$27.98
200-Day Avg
$27.98
Prev Close
$25.63
Open
$26.60
Valuation & Ratios
P/E Ratio
—
EPS
—
P/B Ratio
—
P/S Ratio
—
Debt/Equity
—
Current Ratio
—
Dividend Yield
—
Gross Margin
—
Returns & Efficiency
Return on Equity
—
Return on Assets
—
FCF Yield
—
EV/EBITDA
—
Valuation
APMDhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
123Aug 25Aug 25
Social Signal Score
73
5d
74
1 mentions
—
30d
73
1 mentions
—
60d
73
1 mentions
—
90d
73
1 mentions
—
news: 1
Mentions (1)
- Newsproactiveinvestors.com·5h ago·Positive
Apnimed shares surge on bullish BofA initiation Shares of Apnimed rose 8% Tuesday after BofA Securities initiated coverage of the company with a Buy rating and a $41 price target. The rating is based on a risk-adjusted discounted cash flow analysis of Oxnimbi (AD109), Apnimed's sole asset and an oral therapy for obstructive sleep apnea (OSA).
View source ↗